Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).

International journal of oncology

Volumn 20, Issue 1, 2002, Pages 81-88

  Giovanella, Beppino C ^a   Stehlin, John S ^a   Hinz, Hellmuth R ^a   Kozielski, Anthony J ^a   Harris, Nicholas J ^a   Vardeman, Dana M ^a  

^a St Joseph's Medical Center Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; RUBITECAN;

ANIMAL; ARTICLE; DOG; DRUG ADMINISTRATION ROUTE; DRUG SCREENING; EVALUATION; EXPERIMENTAL NEOPLASM; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HALF-LIFE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL;

MLCS; MLOWN;

EID: 0036134605     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.20.1.81     Document Type: Article

References (0)